Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score
NCT ID: NCT07020546
Last Updated: 2025-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
180 participants
INTERVENTIONAL
2025-07-08
2026-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation
NCT05279560
Ovarian Rejuvenation for Premature Ovarian Insufficiency and Poor Ovarian Response
NCT04163640
Ovarian PRP for Diminished Ovarian Reserve
NCT05790655
Autologous Platelet-rich Plasma to Improve Responsiveness and Embryo Quality in Patients With Poor Ovarian Response
NCT05105724
Injections of Autologous PRP in Women With Primary Ovarian Insufficiency
NCT03542708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Following the first IVF cycle, patients will undergo their first oPRP injection:
* Timing: 1-2 weeks after the onset of the next menstrual cycle.
* Procedure: Under IV sedation, a patient's autologous PRP will be prepared and injected directly into both ovaries under transvaginal ultrasound guidance.
* Second IVF Cycle (oPRP Study Cycle)
* The same ovarian stimulation protocol will be used for consistency.
* A second oPRP injection will be performed on stimulation days 2-5 to enhance folliculogenesis.
* Ovulation will be triggered at the same follicular size thresholds, and oocyte retrieval will follow identical protocols.
* Fertilization methodology will be identical to the first cycle unless no fertilization is identified in the first cycle.
* Embryo Development Analysis: Up to 15 embryos will be cultured in the AI incubator, where time-lapse imaging will track their morphokinetics, and AI-based analysis will assess embryo viability and implantation potential.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Embryo Development Before and After Ovarian PRP Using Time-Lapse AI Embryo Quality Score
Patients will undergo two IVF cycles. The first cycle will be before ovarian PRP treatment and the second will be after. The embryo development measured by data gathered in time-lapse imaging and AI software will be used to determine differences between the groups within the same patient
Ovarian Platelet-rich plasma (PRP) injections
This is a procedure that our patients receive at our clinic. We want to use the AI software to evaluate embryo development before and after treatment to see if there is a difference in embryo quality after PRP treatment within the same patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ovarian Platelet-rich plasma (PRP) injections
This is a procedure that our patients receive at our clinic. We want to use the AI software to evaluate embryo development before and after treatment to see if there is a difference in embryo quality after PRP treatment within the same patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate ovarian reserves and AMH level
* Willingness to undergo two IVF cycles and oPRP treatment
Exclusion Criteria
* Any health conditions that are contraindicated for IVF or oPRP treatment
18 Years
47 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Generation Next Fertility
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jesse Hade, MD
Role: PRINCIPAL_INVESTIGATOR
Generation Next Fertility
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Generation Next Fertility
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IORG0010499-012025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.